EU AstraZeneca Ruling Raises Bar For IP Monopoly Abuse

Law360, New York (December 6, 2012, 9:41 PM EST) -- The European Union's highest court refused Thursday to overturn a €52.5 million ($68 million) abuse of dominance fine against AstraZeneca PLC, but it did raise the bar for the kinds of intellectual property defense tactics that could get a dominant market player into trouble with the bloc's antitrust agency.

The European Court of Justice upheld a 2010 ruling that largely endorsed the European Commission's decision to sanction the pharmaceutical giant for manipulating the drug and patent regulatory systems in order to block generic versions of ulcer...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.